{"publication_id":"3df522c5-e35c-4b1e-b34f-acfcac356e2a","content_hash":"sha256:da5140e612895917827e88519c00505497288f0f3e738346b0e2274f0f2df0ef","nodes":[{"id":"3df522c5-e35c-4b1e-b34f-acfcac356e2a","type":"publication","title":"Resveratrol exercise-mimetic promise versus human training blunting"},{"id":"claim_1","type":"claim","text":"Aging-active consumer market: products marketed to 50+ exercisers as mitochondrial/anti-aging support could in principle blunt rather than boost cardiovascular return on training."},{"id":"claim_2","type":"claim","text":"Sports nutrition and supplement R&D: combining \"exercise-mimetic\" claims with high-intensity protocols warrants human evidence, not rodent extrapolation."},{"id":"claim_3","type":"claim","text":"Aged men only, n=27, 250 mg trans-resveratrol, 8 weeks, high-intensity training; transfer to other ages, sexes, doses, training types, or longer durations is unsupported by the receipts."},{"id":"claim_4","type":"claim","text":"Receipts are limited to a 2006 mouse mechanistic study and a 2013 RCT in 27 aged men. No causal claim for other populations, doses, or training types is supported."},{"id":"source_1","type":"source","study":"Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha","year":2006,"doi":"10.1016/j.cell.2006.11.013","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men","year":2013,"doi":"10.1113/jphysiol.2013.258061","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"3df522c5-e35c-4b1e-b34f-acfcac356e2a","to":"claim_1","type":"contains_claim"},{"from":"3df522c5-e35c-4b1e-b34f-acfcac356e2a","to":"claim_2","type":"contains_claim"},{"from":"3df522c5-e35c-4b1e-b34f-acfcac356e2a","to":"claim_3","type":"contains_claim"},{"from":"3df522c5-e35c-4b1e-b34f-acfcac356e2a","to":"claim_4","type":"contains_claim"}],"screening":{"identified":2,"screened":2,"excluded":0,"included":2,"included_or_retained":2,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"2 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}